• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$50.49 -$0.13 (-0.26%)

REAL-TIME: Last trade at

Gilead Sciences

NASDAQ:GILD

Jump to this page for:

Related Resources

Is This Biotech's Best Stock?

5/27/2012 by DailyFinance

The Meaningless Drug Approval That Could Cost the Industry Billions

5/25/2012 by DailyFinance

Orbimed's $3.4B Filing: 2 Stocks It And Other Healthcare Funds Bought In Q1, And Other Trades

5/24/2012 by Seeking Alpha

Gilead Drug Up for European Review - Analyst Blog

5/24/2012 by Nasdaq

FDA Nod for Merck Drug Label Update - Analyst Blog

5/24/2012 by Nasdaq

Is Bristol a Buy Post-Plavix

5/23/2012 by DailyFinance

Too Little, Too Late for Achillion?

5/22/2012 by DailyFinance

Bristol-Myers Squibb's Thud Heard Round the World

5/20/2012 by DailyFinance

2 Reasons That Cystic Fibrosis Trumps Hep C

5/16/2012 by DailyFinance

The Zacks Analyst Blog Highlights: Gilead Sciences, Abbott Labs, Alliance Data Systems Corporation,

5/15/2012 by Nasdaq

HIV Drug Maker Gilead Sciences Scores Two Wins

5/14/2012 by Minyanville

Good News for Gilead - Analyst Blog

5/14/2012 by Nasdaq

A Step Closer to Quadrific Sales

5/14/2012 by DailyFinance

Gilead Sciences Clears Hurdle for First Pill to Prevent HIV

5/11/2012 by Minyanville

FDA Panel Backs Gilead's HIV 'Quad' Medicine

5/11/2012 by Smart Money

UPDATE: FDA Panel Backs Gilead's HIV 'Quad' Medicine

5/11/2012 by Smart Money

This Biotech Is No One-Trick Pony

5/10/2012 by DailyFinance

Best of the Blogs, Biotech: Will New HIV Prevention Pill Create More Dangerous Strains?

5/10/2012 by Minyanville

FDA: Safety Of Proposed Gilead HIV Drug "Generally Acceptable"

5/9/2012 by Smart Money

WSJ BLOG/Health: A.M. Vitals: GSK's Hostile Human Genome Bid; Regulators Like Preventive HIV Drug

5/9/2012 by Smart Money

1 Biotech With 2 Binary Events in 2 Days

5/9/2012 by DailyFinance

Is Vertex Pharmaceuticals the Perfect Stock?

5/8/2012 by DailyFinance

FDA Appears To Support Gilead HIV Drug As Prevention Tool

5/8/2012 by Smart Money

WSJ BLOG/Health: A.M. Vitals: Autism Shift Won't Leave Kids Behind, Study Says

5/7/2012 by Smart Money

After Hours Most Active for May 4, 2012 : QQQ, BAC, STD, STJ, NEM, GILD, GGC, TOT, SPPI, MSFT, FNFG

5/4/2012 by Nasdaq

Will Gilead Sciences Help You Retire Rich?

5/3/2012 by DailyFinance

Vivus Wins FDA Approval

4/30/2012 by Minyanville

Higher Costs Hurt Gilead - Analyst Blog

4/27/2012 by Nasdaq

Maybe There Will Be Some Hep C Patients Left

4/27/2012 by DailyFinance

Amazon.com, Starbucks results on tap after hours

4/26/2012 by MarketWatch

Celgene Misses, Reaffirms - Analyst Blog

4/26/2012 by Nasdaq

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/26/2012 by Smart Money

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

4/26/2012 by Smart Money

Gilead profit falls after acquisition costs

4/26/2012 by MarketWatch

Pharma & Biotech Stock Outlook - April 2012 - Industry Outlook

4/26/2012 by Nasdaq

TIP SHEET: Janus Fund Tries To Manage Risk Of Drug Stocks

4/25/2012 by Smart Money

Why Did The Market Trip These Stocks Up?

4/24/2012 by DailyFinance

Amgen Kicks Off Week of Big Biotech Earnings

4/24/2012 by Minyanville

Earnings Preview: Celgene - Analyst Blog

4/24/2012 by Nasdaq

A Bad News Buy for Gutsy, Patient Investors

4/24/2012 by DailyFinance
See More Articles...